scholarly journals “Fibromyalgia and quality of life: mapping the revised fibromyalgia impact questionnaire to the preference-based instruments”

2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Daniel Collado-Mateo ◽  
Gang Chen ◽  
Miguel A. Garcia-Gordillo ◽  
Angelo Iezzi ◽  
José C. Adsuar ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Fibromyalgia Impact Questionnaire ◽  
Revised Fibromyalgia Impact Questionnaire

scholarly journals Screening of Anxiety and Depression in Patients With Fibromyalgia From 18 to 65 Years Old and Its Relationship With the Severity of Fibromyalgia and Quality of Life

2018 ◽  
Vol 10 (12) ◽  
pp. 12
Author(s):  
Christian Paternina Gonzalez ◽  
Elias Forero Illera ◽  
Carmen Laborde Cárdenas ◽  
Eduardo Navarro Jimenez ◽  
Pedro Gomez Mendez ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Fibromyalgia Impact Questionnaire ◽  
Sociodemographic Factors ◽  
Cross Sectional Study ◽  
Categorical Variables ◽  
Anxiety And Depression ◽  
Bivariate Analysis ◽  
Health Questionnaire ◽  
Cross Sectional

OBJECTIVE: To identify the relationship between anxiety and depression with the severity of fibromyalgia and quality of life in patients aged 18 to 65 years, clinic of rheumatology of Barranquilla. METHODS: Observational, descriptive, comparative cross-sectional study. Patients with fibromyalgia who attend the external consultation of rheumatology will be surveyed. The questionnaires to be applied are the Fibromyalgia Impact Questionnaire Revised (Spanish version), Health Questionnaire SF-36, Patient Health Questionnaire and a Scale of 7 questions for generalized anxiety disorder. The data collected in this descriptive study will be analyzed by means of frequency and association measures. The analysis of association between sociodemographic factors and clinical characteristics will be carried out with bivariate analysis and the comparison of qualitative or categorical variables will be done through the analysis of variance, to compare variables of ordinal type and variables of type ratio. RESULTS: 34.2% of the patients did not present anxiety whereas 83.6% of the patients had some degree of depression. 50% of the patients had moderate, severe and extreme degrees of depression. An association was found between severity of fibromyalgia with anxiety, depression and quality of life (p <0.05). CONCLUSION: A directly proportional relationship was found between the severity of depression and anxiety and the severity of FM. An elevated score in the FIQR, lower weighted scores for quality of life in the participants, in addition to greater severity in the scales GAD - 7 and PHQ - 9, all score to lower quality of life.

scholarly journals Calidad de vida en pacientes con fibromialgia. Revisión bibliográfica

2019 ◽  
pp. 4-10
Author(s):  
Carla Del Olmo Climent ◽  
María Cuerda Ballester ◽  
David Sancho Cantus
Keyword(s):  
Quality Of Life ◽  
Sedentary Lifestyle ◽  
Fibromyalgia Impact Questionnaire ◽  
State Of Health ◽  
Level Of Education ◽  
Calidad De Vida ◽  
Comprehensive Knowledge ◽  
Observational Design ◽  
The Impact

Abstract Objective: To describe the impact of fibromyalgia on the state of health and quality of life of people affected by fibromyalgia (FM). Method: Literature review of studies on the quality of life related to health in people with FM, evaluated with validated instruments. Results: Thirty-one studies were analyzed, which were mainly of transversal observational design. The most affected dimensions were physical function, pain and mental state. The factors like sedentary lifestyle and physical activity were significant in this population. The prevalence of Fibromyalgia was significantly higher in women, married, with low level of education and housewives. The most used instrument to measure quality of life related to health was the Fibromyalgia Impact Questionnaire (FIQ). Conclusions: the parameters studied have allowed to assess the needs of patients and achieve a more comprehensive knowledge of the process of this disease. Keywords: fibromyalgia, quality of life, pain, rheumatic diseases.

scholarly journals Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Pain Medicine ◽  
2020 ◽  
Vol 21 (10) ◽  
pp. 2212-2218
Author(s):  
Carolina Chaves ◽  
Paulo Cesar T Bittencourt ◽  
Andreia Pelegrini
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Placebo Group ◽  
Low Cost ◽  
Fibromyalgia Impact Questionnaire ◽  
Health Condition ◽  
Depression Score ◽  
Controlled Clinical Trial ◽  
Double Blind

Abstract Objective To determine the benefit of a tetrahydrocannabinol (THC)-rich cannabis oil on symptoms and quality of life of fibromyalgia patients. Methods A double-blind, randomized, placebo-controlled clinical trial was conducted for eight weeks to determine the benefit of a THC-rich cannabis oil (24.44 mg/mL of THC and 0.51 mg/mL of cannabidiol [CBD]) on symptoms and quality of life of 17 women with fibromyalgia, residents of a neighborhood with a low socioeconomic profile and a high incidence of violence in the city of Florianopolis, Brazil. The initial dose was one drop (∼1.22 mg of THC and 0.02 mg of CBD) a day with subsequent increases according to symptoms. The Fibromyalgia Impact Questionnaire (FIQ) was applied at pre- and postintervention moments and in five visits over eight weeks. Results There were no significant differences on baseline FIQ score between groups. However, after the intervention, the cannabis group presented a significant decrease in FIQ score in comparison with the placebo group (P = 0.005) and in comparison with cannabis group baseline score. (P < 0.001). Analyzing isolated items on the FIQ, the cannabis group presented significant improvement on the “feel good,” “pain,” “do work,” and “fatigue” scores. The placebo group presented significant improvement on the “depression” score after intervention. There were no intolerable adverse effects. Conclusions Phytocannabinoids can be a low-cost and well-tolerated therapy to reduce symptoms and increase the quality of life of patients with fibromyalgia. Future studies are still needed to assess long-term benefits, and studies with different varieties of cannabinoids associated with a washout period must be done to enhance our knowledge of cannabis action in this health condition.

Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients

2019 ◽  
Vol 18 (4) ◽  
pp. 326-333 ◽  
Author(s):  
Vittorio Schweiger ◽  
Alvise Martini ◽  
Paola Bellamoli ◽  
Katia Donadello ◽  
Carlo Schievano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Observational Study ◽  
Fibromyalgia Syndrome ◽  
Fibromyalgia Impact Questionnaire ◽  
Retrospective Observational Study ◽  
Visual Analogue Scale Pain ◽  
Change Over Time ◽  
Ultramicronized Palmitoylethanolamide ◽  
Over Time

Background: Fibromyalgia syndrome is a chronic multifaceted disease characterized by widespread pain, muscle stiffness, fatigue, unrefreshing sleep and cognitive disorders. To date, no medication has been shown to significantly improve pain, associated symptoms and Quality of Life in fibromyalgic patients. Methods: In this retrospective observational study, we analyzed data regarding 407 patients with diagnosis of fibromyalgia syndrome who between 2013 and 2016 have been prescribed orally ultramicronized palmitoylethanolamide tablets (Normast® Epitech Group SpA, Saccolongo, Italy) regardless of the concomitant pharmacological therapy (add-on treatment). Results: Regarding efficacy, in the 359 analyzed patients, the change over time in Visual Analogue Scale pain score was statistically significant, ranging from 75.84 (±15.15) to 52.49 (±16.73) (p<0.001). Regarding quality of life, the change over time in Fibromyalgia Impact Questionnaire score was statistically significant, ranging from 68.4 (±14.1) to 49.1 (±19.6) (p<0.001). In the treated population, only 36 patients (13,7%) reported Adverse Events predominantly of gastrointestinal type (diarrhea, dyspepsia, bloating, constipation, vomiting). Globally, 151 patients (57,63%) left the treatment due to inefficacy. Conclusion: The results of ultramicronized palmitoylethanolamide treatment in this retrospective analysis represent an important step for the development of a new and well-tolerated therapy for fibromyalgia syndrome, mostly suitable for these patients who need long-term treatments. Further methodologically stronger studies will be necessary to validate our observation.

Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series

2014 ◽  
Vol 5 (2) ◽  
pp. 63-71 ◽  
Author(s):  
Heinrich Wernze ◽  
Thomas Herdegen
Keyword(s):  
Quality Of Life ◽  
Rating Scale ◽  
Dose Range ◽  
Fibromyalgia Impact Questionnaire ◽  
Case Series ◽  
Treatment Resistant ◽  
Positive Effects ◽  
Long Term Treatment

AbstractObjectiveNo single drug is broadly efficacious in the long-term treatment of fibromyalgia syndrome (FMS). Spironolactone is known to ameliorate mood and tension headache or migraine in women with premenstrual syndrome or clinical signs of hyperandrogenism. In a case series of women with treatment resistant FMS spironolactone was therefore added to their medication, and they were observed for at least 12 months.Methods31 women with treatment-resistant FMS received spironolactone as add-on medication to various pain modulating drugs. 15 women responded to spironolactone and baseline data were compared with assessments over 12–14 months on treatment with spironolactone (ALDACTONE®) in dose range 100–200 mg/day. The efficacy was evaluated by the fibromyalgia impact questionnaire (FIQ) total score and 8 FIQ subtests, a German mood inventory (BSKE-EWL), and further assessments of changes in relevant psychological and physical complaints. 16 women had no effect and stopped the treatment early.ResultsThe subsequent data refer to the 15 responders. The FIQ total score (maximal score = 80) decreased from 56.6 ± 10.0 at baseline to 17.1 ± 11.9 (mean ± SD) 12–14 months later, and pain intensity on an 11 point numeric rating scale (NRS) decreased from 8.8 ± 1.6 to 2.6 ± 1.9 (mean ± SD). Similar changes in FIQ subscores were found for fatigue, morning tiredness, stiffness, anxiety, and depression. Emotional functioning consistently improved: positive mood from 20.0 ± 5.4 to 37.7 ± 5.4 (maximal score = 48), and negative mood from 35.4 ± 5.3 to 10.0 ± 4.4 (maximal score = 60) (each mean ± SD) as well as other mental and physical dysfunctions including non-restorative sleep. All these changes at 4–6 weeks remained on this level for 11–13 months. The drug was well-tolerated and safe, no serious adverse effects were observed. Regular monitoring of serum potassium did not reveal hyperkalemia. All 15 women were able to reduce or discontinue concomitant drugs.ConclusionFifteen of 31 women with otherwise treatment-resistant FMS experienced a number of prolonged beneficial effects from spironolactone on their complex pain-condition.Implications and discussionWe hypothesise that spironolactone affects several central and peripheral neurotransmitter systems such as γ-aminobutyric acid (GABA) activity and dopaminergic transmission. The high rate of non-responsive patients underlines that FMS may represent several subgroups. Pain relief and improvement of associated FHS-symptoms and positive effects on additional diseases or dysfunctions give reasons for marked and sustained improvement in the quality of life.Well-controlled, double-blind, and randomised trials are necessary to confirm our potentially very important observations.

scholarly journals A study protocol for a randomized controlled trial of an anti-inflammatory nutritional intervention in patients with fibromyalgia

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Ana Rita Silva ◽  
Alexandra Bernardo ◽  
Maria Fernanda de Mesquita ◽  
José Vaz Patto ◽  
Pedro Moreira ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sleep Quality ◽  
Inflammatory Markers ◽  
Short Form ◽  
Fibromyalgia Impact Questionnaire ◽  
Nutritional Intervention ◽  
Disease Assessment ◽  
Control Group ◽  
Anti Inflammatory

Abstract Background This study aims to analyze the effects of a potentially anti-inflammatory nutritional intervention in disease assessment parameters, inflammatory markers, and quality of life of fibromyalgia (FM) patients. Methods A sample of 100 female patients diagnosed with FM, followed up at Portuguese Institute of Rheumatology (IPR) in Lisbon, is being randomly allocated in two groups. Patients in the intervention group are adopting an anti-inflammatory diet, characterized by the exemption of the intake of foods containing gluten, dairy, sugar, and ultra-processed foods, during 3 months. During the first month, a low fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) diet is implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months. Patients in the control group are adopting a diet based on general recommendations for healthy eating. The outcomes are pain, fatigue, quality of sleep, quality of life, gastrointestinal symptoms, and inflammation. Before and after the 3 months intervention, and also 1 month after beginning the intervention, the following questionnaires are applied: Revised Fibromyalgia Impact Questionnaire, visual analog pain scale, Brief Pain Inventory,visual analog scale from a list of common gastrointestinal and extraintestinal symptoms in FM, Short Form 36, Fatigue Severity Survey, and Pittsburg Sleep Quality Index. Ultra-sensitive serum C-reactive protein, eritrocyte sedimentation rate, and interleukin-8 are determined. Age, physical activity, anthropometric parameters, and body composition are being collected. Student’s t test will assess the association between the disease evaluation parameters, the inflammatory markers, and the dietary interventions. Discussion The results of this study are expected to determine whether a change in patient nutrition helps to alleviate symptoms, which would optimize medical intervention. Trial registration www.ClinicalTrials.gov NCT04007705. Registered on July 5, 2019.

scholarly journals Main symptoms associated to the catastrophizing in women with fibromyalgia and migraine

2020 ◽  
pp. 39-43
Author(s):  
Amanda de Oliveira Freire Barros ◽  
Manuella Moraes Monteiro Barbosa Barros ◽  
Reydiane Rodrigues Santana ◽  
Débora Wanderley ◽  
Angélica da Silva Tenório ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Physical Activity ◽  
International Physical Activity Questionnaire ◽  
Pain Catastrophizing ◽  
Fibromyalgia Impact Questionnaire ◽  
Depression And Anxiety ◽  
Quality Of Sleep ◽  
Perception Of Quality ◽  
Activity Questionnaire

ObjectiveTo evaluate the main symptoms associated catastrophizing in women with fibromyalgia and migraine.MethodologyWe conducted an observational study with 26 women diagnosed with both fibromyalgia and migraine, aged between 30 and 60 years (46±8 years). The Pain Catastrophizing Scale was applied as a cut-of point =30, dividing the volunteers in groups with (n=18) and without catastrophizing (n=8). We assessed the quality of sleep (Pittsburgh sleep quality index), the presence of depression and anxiety (Becks depression and anxiety inventories), the quality of life perception (Fibromyalgia impact questionnaire-revised), the disability due to migraine (Migraine disability assessment) and the level of physical activity (International physical activity questionnaire).ResultsThe time of fibromyalgia did not difer (p=0.80) between the group with (8.54±4.88) and without catastrophizing (10.04±3.47). The Fibromyalgia impact questionnaire-revised scores were significantly higher (p=0.01) among women with catastrophizing (78±12.6) than those without (56.6±22.3). There was no diference between the groups (p>0.05) in relation to the other outcomes evaluated.ConclusionThe presence of catastrophizing in women with fibromyalgia and migraine are associated with a worse perception of quality of life. a worse perception of quality of life.

scholarly journals Strengthening exercises using swiss ball improve pain, health status, quality of life and muscle strength in patients with fibromyalgia: a randomized controlled trial

Reumatismo ◽  
2021 ◽  
Vol 73 (1) ◽  
pp. 15-23
Author(s):  
J.S. Arakaki ◽  
F. Jennings ◽  
G.Q. Estrela ◽  
V.d.G. Cruz Martinelli ◽  
J. Natour
Keyword(s):  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Health Status ◽  
Muscle Strength ◽  
Controlled Trial ◽  
Fibromyalgia Impact Questionnaire ◽  
Randomized Controlled ◽  
Strengthening Exercises ◽  
Swiss Ball

The aim was to evaluate the effectiveness of strengthening exercises using the Swiss ball in patients with fibromyalgia through a randomized controlled trial with intention to treat analyses. A total of 60 patients with fibromyalgia met the inclusion criteria and were randomly allocated to either the Swiss ball exercise group (n=30) or a stretching group (n=30). All patients participated in 40-minute training sessions 3 times per week for 12 weeks. Pain (Visual Analogue Scale 0-100); muscle strength (One Repetition Maximum test); health status (Fibromyalgia Impact Questionnaire Revised); quality of life (Short Form-36 questionnaire) were evaluated at baseline, and after 6 and 12 weeks of training. The Swiss ball group showed a statistically significant improvement in VAS (0-100) (p<0.001), SF-36 (p<0.05) and Fibromyalgia Impact Questionnaire (p<0.001) compared with the stretching group. The results of this study proved that the treatment for fibromyalgia with strengthening exercises and the use of the Swiss ball led to improvement of pain, quality of life, muscle strength and decreased the need for medications for this disease compared to stretching exercises, without negative effects.

Sign in / Sign up

Export Citation Format

Share Document